Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harvard Bioscience (NQ: HBIO )

2.400 +0.050 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harvard Bioscience

< Previous 1 2 Next >
HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024
HBIO stock results show that Harvard Bioscience missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Holley And 2 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
HBIO Stock Earnings: Harvard Bioscience Meets EPS, Misses Revenue for Q1 2024
HBIO stock results show that Harvard Bioscience met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
HBIO Stock Earnings: Harvard Bioscience Misses EPS, Misses Revenue for Q4 2023
HBIO stock results show that Harvard Bioscience missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Preview For Harvard Bioscience
Via Benzinga
Preview: Harvard Bioscience's Earnings
Via Benzinga
Why Harvard Bioscience Stock Rose This Week
The company reported improved revenue in Q1. 
Via The Motley Fool
Harvard Bioscience's Return On Capital Employed Overview
Via Benzinga
Earnings Preview: Harvard Bioscience
Via Benzinga
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
A Preview Of Harvard Bioscience's Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Over $7M Bet On This Consumer Defensive Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by more than 250 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
10 Stocks Under $10 for 2023
In 2023, the only certainty will be uncertainty. Investors should keep their portfolios flexible with these stocks under $10. 
Via InvestorPlace
Earnings Preview: Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Harvard... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million. 
Via Benzinga
$92 Million Bet On This Penny Stock? Also Check Out Other 3 Stocks Under $5 Insiders Are Buying
U.S. initial jobless claims dropped by 2,000 to 250,000 the week ended August 13th. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 39 companies reached new 52-week lows. 
Via Benzinga
Looking Into Harvard Bioscience's Return On Capital Employed
Harvard Bioscience (NASDAQ:HBIO) brought in sales totaling $28.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 815.92%, resulting in a loss of $6.88... 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Recap: Harvard Bioscience Q1 Earnings
Harvard Bioscience (NASDAQ:HBIO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Harvard Bioscience: Q4 Earnings Insights
Harvard Bioscience (NASDAQ:HBIO) reported its Q4 earnings results on Tuesday, March 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million. •... 
Via Benzinga
Earnings Preview: Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Outlook For Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.